Malignant Hyperthermia

12345678910111213141516171819
Across
  1. 2. Activate the medical emergency response system for clinical area and call ________hotline.
  2. 4. Ryanodex should be administered within ___ minutes of diagnosis.
  3. 5. ________ unexplained is another acute sign of MH.
  4. 7. Halothane ___________Contracture test is used to confirm MH.
  5. 10. MH is triggered by exposure to ___________ gases (Desflurane, Isoflurane, Sevoflurane, Haloflurane and succinylcholine)
  6. 11. each 250mg vial of Ryanodex must be reconstituted with ____ml sterile water for injection.
  7. 12. _____ for signs/symptoms of MH for 48 hrs (including vitals, muscle rigidity, dysrhythmias, cyanosis, tachypnea, rapid rising core temperature, cola colored urine)
  8. 13. MH Cart is located between the OR and _______.
  9. 15. first dose fo Ryanodex as 2.5mg/kg iv push ____ though a large bore IV is recommended.
  10. 16. Malignant hyperthermia is a rare __________ disorder.
  11. 18. The underlying cause is the intracellular release of ____________.
  12. 19. there are no _____-specific MH carts.
Down
  1. 1. After the anesthesia provider notifies the surgeon of a possible MH crisis, the anesthesia provider should immediately ________ use of all volatile agents.
  2. 3. _________ is a formulation of dantolene that can be reconstituted and used for a MH crisis at CCUH.
  3. 6. Anesthesia breathing system connects the patient’s airway to the anesthetic machine creating an _________ atmosphere.
  4. 7. _______ saline is available in the anesthesia work room refrigerator and pharmacy.
  5. 8. A high risk patient for MH is a ___ degree relative of anyone known to MHS or have a positive muscle biopsy.
  6. 9. Acute sign of MH is unexplained _____ muscle rigidity.
  7. 11. For any patient that is susceptible to MH the OR should obtain a clean _________ ABS and exchange the existing ABS.
  8. 14. MH is characterized by sever hyper-metabolic state and ____ of the skeletal muscles.
  9. 17. any non-stimulating _______ anesthetic can be used on a MH susceptible patient.